Work

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Year: 2013

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2013.04.465

Authors: R. Coleman, M. Sill, C. Aghajanian, H. Gray, K. Tewari, S. Rubin, T. Rutherford, J. Chan, E. Swisher

Institutions: The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Group, Memorial Sloan Kettering Cancer Center, University of Washington Medical Center, University of California, Irvine, University of California, Irvine Medical Center, University of Pennsylvania, Yale University, University of California, San Francisco

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4241586731

FWCI: 0.316

Cites:

Cited by: 3

Related to: 10